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Abstract
Background: Circulating tumor cells (CTC) and disseminated tumor cells (DTC) are thought to be responsible for 
metastasis, so the detection of CTC may serve as individual prognostic factor in patients suffering from colorectal 
cancer. Therefore, a series of immunomagnetic enrichment methods for CTC have been developed using a variety of 
monoclonal antibodies against the Epithelial Cell Adhesion Molecule (EpCAM). However, it remains unclear whether all 
commercially available EpCAM antibodies show the same sensitivity and specificity. Furthermore, it remains unclear 
which method of sample preparation and cell extraction is most suitable for immunomagnetic enrichment and 
detection of CTC. In this study, we aimed to investigate whether the detection of CTC by a cytokeratin 20 reverse 
transcriptase-polymerase chain reaction (CK20 RT-PCR) may be influenced by the use of various Epithelial Cell 
Adhesion Molecule (EpCAM) antibodies for immunomagnetic isolation of CTC.
Results: Using both EpCAM antibodies (mAb BerEP4 and mAb KS1/4) for immunomagnetic enrichment in blood 
samples of 39 patients with colorectal cancer we found heterogenous results in each patient with regard to tumor cell 
detection. In the tumor cell spiking experiments with whole blood samples the sensitivity of the CK 20 RT-PCR assay 
was higher using immunomagnetic beads coated with mAb KS1/4 compared to precoated mAb BerEP4 Dynabeads. 
Extraction of MNC fraction with Ficoll gradient centrifugation prior to immunomagnetic enrichment resulted in a 
higher sensitivity of the CK 20 RT-PCR assay.
Conclusions: We concluded that isolation and detection of CTC with immunomagnetic enrichment methods is 
critically dependent on the used EpCAM clone. Further studies with a larger number of patients should clarify if the 
enrichment protocol influences the prognostic value of the tumor cell detection protocol.
Background
Detection of circulating tumor cells (CTC) in blood and
disseminated tumor cells (DTC) in the bone marrow and/
or lymph nodes, which are thought to be responsible for
metastases, may allow a better prediction of the individ-
ual prognosis of patients with colorectal cancer [1-3].
Recent studies of our group indicated that the molecular
detection of CTC and DTC in patients with colorectal
cancer (CRC) may be of prognostic value [4-7]. Further-
more, immunomagnetic enrichment strategies have been
developed to improve the detection and yield of CTC and
DTC [8]. A large number of monoclonal antibodies
(mAb) against the Epithelial Cell Adhesion Molecule
(EpCAM) which is expressed only in epithelium and
malignant tumors derived from epithelia have been
increasingly used to enrich and isolate CTC from blood
and DTC from bone marrow samples [9,10]. However,
there are no data available comparing antibodies against
various EpCAM epitopes for immunomagnetic isolation
of CTC with regard to their sensitivity and specificity.
Therefore, it remains unclear if all anti-EpCAM antibod-
ies are able to detect and to capture the same range of
CTC and if they have the same clinical and prognostic
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impact. Furthermore, it is still unknown which method of
sample preparation and cell extraction is most suitable
for immunomagnetic enrichment and detection of CTC.
In this study, we aimed to compare two different spe-
cific antibodies against the epitope in the EGF-like
domain I of EpCAM for immunomagnetic enrichment
and subsequent detection of CTC in CRC patients. We
used commercially available immunomagnetic beads
coated with mAb BerEP4 [11] and magnetic beads coated
with mAb KS1/4 [12]. Both monoclonal antibodies recog-
nize specific epitopes of the extracellular domain of the
EpCAM molecule. mAb BerEP4 recognizes two (34 kDa
and 39 kDa) specific antigens, whereas mAb KS1/4 recog-
nizes one (40 - 42 kDa) specific antigen of the extracellu-
lar domain of the EpCAM molecule [10]. Furthermore,
we examined the effect of two different cell extraction
protocols on subsequent immunomagnetic enrichment
and detection of tumor cells in the blood.
Results
Specificity of the enrichment and extraction protocols
Both whole blood and MNC fractions of five healthy
donors were tested regarding the specificity of cell extrac-
tion and enrichment protocols with immunomagnetic
beads coated with BerEP4 and KS1/4. No CK20 signal
was observed in all examined blood samples of healthy
donors, demonstrating the specificity of the used assays.
Sensitivity of the enrichment and extraction protocols
Whole Blood
In the tumor cell spiking experiments with whole blood
samples the sensitivity of the CK20 RT-PCR assay was
higher using immunomagnetic beads coated with mAb
KS1/4 compared to precoated mAb BerEP4 Dynabeads.
In serial dilution assays, a minimum number of 104 HT29
c e lls c ould be det ect ed in 5 ml whole blood using the
BerEP4 mAb whereas 103 HT29 cells could be detected in
the same volume using the KS1/4 mAb.
Mononuclear cell fraction
Extraction of MNC fraction with Ficoll gradient centrifu-
gation prior to immunomagnetic enrichment of blood
samples spiked with HT29 cells resulted in a higher sensi-
tivity of the CK20 RT-PCR assay. 103 HT29 cells spiked in
5 ml blood (200 cells/ml) could be detected after isolation
of the MNC fraction using the mAb BerEP4 Dynabeads,
whereas 102 HT29 cells spiked in 5 ml blood (20 cells/ml)
were detected using the mAb KS1/4 coated beads.
Blood spiking experiments were repeated several times
to confirm the above mentioned results.
The observed higher sensitivity of tumor cell detection
after isolation of the MNC fraction prior to immunomag-
netic CTC enrichment prompted us to generally use
Ficoll gradient centrifugation before further immuno-
magnetic enrichment and detection of CTC in the blood
of CRC patients.
Detection of tumor cells in blood samples of CRC patients
Median age of included CRC patients was 63 years (range
27 - 90) with 16 females and 23 males. Eighteen of 39
(46%) patients presented with metastatic disease to the
liver and were classified as UICC stage IV; 7 patients were
UICC stage III, and 7 patients stage UICC II and I. Clini-
cal data of the patients are shown in Table 1.
Using two different antibodies (mAb BerEP4 and mAb
KS1/4) for immunomagnetic enrichment, CTC were
detected in 11 of 39 (28%) patients with CRC. Among
these, immunomagnetic enrichment with mAb BerEP4
beads accounted for 6 CK20 positive patients. Immuno-
magnetic enrichment using mAb KS1/4 beads showed 5
CK20 positive patients. Interestingly, there were no blood
samples being CK 20 positive for both used antibodies
(Table 2 and Figure 1).
CK20 PCR transcripts were detected in 3 of 18 (17%)
blood samples from UICC stage IV patients after immu-
nomagnetic enrichment with mAb KS1/4 coated beads.
When mAb BerEP4 beads were used, we also observed
positive CK20 products in 3 of 18 (17%) UICC stage IV
patients. Among the 7 patients with UICC stage III, 3
patients showed CK20 positive samples after enrichment
of CTC with BerEP4 beads only. Positive CK20 signals
were observed in 2 of 7 patients with UICC stage I after
enrichment with KS1/4 coated beads only (see Table 3).
Furthermore, among 7 patients with UICC stage II no
samples were found positive for CK20 using either
BerEP4 or KS1/4 coated beads.
Discussion
The first phase of the metastatic process of malignant
epithelial tumors consists of local tumor cell migration,
followed by tumor cell dissemination in the blood, inva-
sion and homing to secondary distant organs [13,14].
Despite recent developments of various therapeutic
approaches, distant metastases represent the major cause
of death in patients with colorectal cancer [14]. Theoreti-
cally, postoperative metastatic recurrence should develop
from isolated tumor cells or micrometastases already
existing at time of surgery or they can derive from tumor
cells that are hematogenously shed into circulation dur-
ing surgical procedures. Thus, a reliable detection
method for CTC in a small volume of peripheral blood
might be of high interest to improve staging and to more
accurately predict patients' individual prognosis. To
increase the specificity of tumor cell detection, immuno-
magnetic beads labeled with an epithelium-specific
monoclonal antibody (mAb) haven been used to isolate
CTC from blood [15].Antolovic et al. BMC Biotechnology 2010, 10:35
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Table 1: Clinical data of our patient cohort with colorectal cancer.
Pat. No. Age Gender Tumor Location TNM UICC Multimodal 
Therapy 
before 
Surgery
Therapy
1 67 F Metachronous liver metastasis 
from Colon Cancer
Tx Nx M1 IV adjuvant Liver resection
2 81 M Rectum T3 N2 M0 III no Anterior Rectal Resection
3 63 F Rectum T1 N0 M0 I no Anterior Rectal Resection
4 65 M Rectum T3 N0 M0 II neoadjuvant Anterior Rectal Resection
5 71 M Colon, right T2 N0 M0 I no Colectomy, right
6 60 M Synchronous liver metastasis 
from Rectal Cancer
T2 N0 M1 IV no Anterior Rectal Resection
7 45 F Colon, left T4 N1 M0 III no Colectomy, left
8 68 F Colon, right T1 N0 M0 I no Colectomy, right
9 68 M Metachronous liver metastasis 
from Rectal Cancer
Tx Nx M1 IV neoadjuvant Liver resection
10 78 F Local Relapse of Rectal Cancer T4 N0 M0 II adjuvant Abdominoperineal Rectal 
Resection and IORT*
11 62 M Rectum T3 N0 M0 II no Anterior Rectal Resection
12 53 M Metachronous liver metastasis 
from Colon cancer
Tx Nx M1 IV adjuvant Hemihepatectomy, right
13 64 M Synchronous liver and lung 
metastasis from Colon Cancer
T4 N2 M1 IV no palliative Colectomy, right
14 45 M Local Relapse of Rectal Cancer T3 N0 M0 II adjuvant Anterior Rectal Resection 
and IORT*
15 74 F Colon, left T1 N0 M0 I no Colectomy, left
16 52 M Colon, left T1 N0 M0 I no Colectomy, left
17 78 M Colon, right T3 N1 M0 III no Colectomy, right
18 72 F Colon, right T1 N0 M0 I no Colectomy, right
19 54 F Colon, left T4 N0 M0 II no Anterior Rectal Resection 
and IORT*
20 54 F Metachronous liver metastasis 
from Colon Cancer
Tx Nx M1 IV adjuvant Hemihepatectomy, right
21 64 F Metachronous liver metastasis 
from Rectal Cancer
Tx Nx M1 IV no palliative loop-Ileostomy
22 44 M Synchronous liver metastasis 
from Colon Cancer
T3 N2 M1 IV no Anterior Rectal Resection
23 73 M Metachronous liver metastasis 
from Rectal Cancer
Tx Nx M1 IV no palliative loop-Ileostoma
24 63 M Metachronous liver metastasis 
from Colon Cancer
T3 N0 M1 IV adjuvant Rectosigmoid Resection
25 27 M Colon, right T4 N2 M0 III no Colectomy, right
26 68 F Colon, right T3 N1 M0 III no Colectomy, right
27 47 M Rectum T3 N1 M0 III neoadjuvant Anterior Rectal Resection 
and IORT*
28 68 M Synchronous liver and bone 
metastasis from Colon Cancer
Tx Nx M1 IV no palliative Bypass 
Ileotransversostomy
29 76 M Metachronous liver metastasis 
from Colon Cancer
Tx Nx M1 IV adjuvant Liver resection
30 62 M Metachronous liver metastasis 
from Colon Cancer
Tx Nx M1 IV adjuvant Exploration, BiopsyAntolovic et al. BMC Biotechnology 2010, 10:35
http://www.biomedcentral.com/1472-6750/10/35
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To our knowledge, this is the first study reporting the
use of mAb KS1/4 coated beads to isolate CTC from CRC
patients. The sensitivity of the KS1/4 coated bead system
was evaluated by HT29 tumor cell dilution experiments
and reproducibly allowed the detection of about 102
HT29 cells spiked in 5 ml blood. In our reference experi-
ments, mAb KS1/4 retrieved 10 fold more tumor cells
than the commonly used mAb BerEP4 precoated beads
(103 cells in 5 ml blood) after MNC gradient enrichment.
Our study also confirmed the study from Guo et al.
which showed better results for MNC population extrac-
tion prior to immunomagnetic isolation of tumor cells
than the immunomagnetic isolation of circulating tumor
cells from whole blood [16]. Guo et al. combined immu-
nomagnetic isolation followed by real-time RT-PCR to
detect CTC in patients with colorectal cancer. This study
showed that combining negative (CD45 depletion) and
positive (CTC enrichment with BerEP4 beads) immuno-
magnetic selection successively yields a high amount of
CTC (1 CTC/1 ml blood). As they used CEA as marker
gene in their analyses, the authors did not assess the
cytokeratin expression of the CTC, which is in our opin-
ion the most widely used marker for CTC [16]. Moreover,
negative enrichment with CD45 depletion of leucocytes
may lead to a theoretical "loss" of CTC as they could stick
together with the leucocytes-beads complexes. Denis et
al. demonstrated CTC in whole blood samples in 4 of 5
patients with metastatic CRC using mAb BerEP coated
magnetic beads and subsequent analysis with RT-PCR
assays for CK8, CK19 and CK20 gene expression [15].
However, the previously described epithelial and tumor
markers can also be expressed in normal peripheral blood
leukocytes normally present in whole blood which may
lead to false positive results [16-21]. Using spiking experi-
ments with healthy donor blood Vlems et al. demon-
strated that differences in sample handling and assay
sensitivity influence CK20 detection in blood [22]. In the
present study, isolation of CTC from CRC patients was
only performed in the MNC population after Ficoll-gra-
dient enrichment. In addition, Ficoll-gradients purge the
MNC fraction from granulocytes, which constitutively
express CK20 mRNA [19]. This is in accordance with our
results as our nested RT-PCR retrieved consistently nega-
tive CK20 results in blood samples from healthy donors.
Automated systems for immunomagnetic CTC isolation
and subsequent immunocytochemical detection are now-
adays available and usually rely on the principle of
EpCAM based enrichment methods. Using the Cell
Search system (Veridex) Cohen et al. demonstrated the
prognostic value of CTC enumeration in the peripheral
blood of metastatic CRC patients [23]. Future studies are
Figure 1 Cytokeratin 20 RT-PCR amplification products after im-
munomagnetic enrichment with both Ep-CAM antibodies from 
blood samples of two CRC patients. W, water negative control; Pos 
positive control (HT29 cells); Neg, negative control (blood of healthy 
person); L, ladder (molecular weight marker). Lanes A1-A2, patient ID 
22 and Lanes B1-2, patient ID 23. A2 and B2 show CK20 products after 
CTC enrichment with KS1/4 beads whereas BerEP4 beads failed to de-
tect CTC in the same patients (A1 and B1).
31 62 M Rectum T1 N0 M0 I no Anterior Rectal Resection
32 78 F Metachronous liver metastasis 
from Rectal Cancer
Tx Nx M1 IV no Segment 2 and 3 Liver 
resection
33 80 M Colon, left T4 N0 M0 II no Anterior Rectal Resection
34 86 F Rectum T3 N0 M0 II no Anterior Rectal Resection
35 44 F Local Relapse Colon Cancer, 
Peritonealcarcinosis
T4 N2 M1 IV adjuvant Laparotomy and Biopsy
36 90 F Colon, left T4 N1 M0 III no Colectomy, left
37 55 M Metachronous liver metastasis 
from Rectal Cancer
Tx Nx M1 IV adjuvant Hemihepatectomy, right
38 56 M Synchronous liver metastasis 
from Colon Cancer
T4 N1 M1 IV adjuvant Hemihepatectomy, left
39 63 F Metachronous liver metastasis 
from Rectal Cancer
Tx Nx M1 IV adjuvant Hemihepatectomy, right
*Abbreviations: IORT: intraoperative radiotherapy; F: female; M: male; Pat. No.: Patients number.
Table 1: Clinical data of our patient cohort with colorectal cancer. (Continued)Antolovic et al. BMC Biotechnology 2010, 10:35
http://www.biomedcentral.com/1472-6750/10/35
Page 5 of 8
needed to examine and compare the detection rates and
prognostic differences between PCR based and immuno-
cytochemical tumor cell detection methods after immu-
nomagnetic enrichment of CTC.
BerEP4 and KS1/4 are high affinity and specific mAb
frequently used to detect EpCAM positive cells. Interest-
ingly, we noted that CK20 RT-PCR products were com-
monly not found in both samples when analyzing blood
of the same patient after enrichment with either mAb
BerEP4 or mAb KS/4. Other authors have already
described heterogeneity in reactivity of EpCAM specific
antibodies. Balzar et al. suggested that different confor-
mational states of the cell surface EpCAM protein might
hide some epitopes leading to subpopulations of EpCAM
and thus heterogeneous affinity [10].
Successful CTC enrichment depends on the level of
EpCAM expression in the target cell [24]. Furthermore,
downregulation of cytokeratins in tumor derived cell
lines and cytokeratin negative CTC have also been
reported in patients with breast cancer [25,26]. These
findings might hinder the adequate detection of CTC.
Promising results for the detection of CK20 positive CTC
in colorectal cancer patients were shown by Wong et al
[27] by blocking the Fc region of the anti-BerEP4 anti-
body with a goat anti-mouse antibody during immuno-
magnetic enrichment. Using this refined
immunomagnetic enrichment method Wong et al. could
demonstrate a specific detection of colorectal CTC in
vitro and they confirmed the clinical significance of their
results in large series of colorectal cancer patients [27].
The dissimilar capture of CTC by BerEP4 and KS1/4
mAbs in our analysis might be explained by various
expression of the EpCAM molecule among the examined
patients. Nevertheless, our KS1/4 system was able to
retrieve 10 fold more CTC compared to the BerEP4 sys-
tem. The use of different EpCAM clones might enhance
Table 2: Characteristics of the CK20 positive patients and comparison of the two different antibodies used for 
immunomagnetic enrichment
Pat. No. Diagnosis TNM UICC-Stage BerEP4-Beads KS 1/4-Beads
2 Rectal Cancer T3 N2 M0 III positive negative
5 Left Colon Cancer T2 N0 M0 I negative positive
9 Metachronous liver metastasis from 
Rectal Cancer
Tx Nx M1 IV positive negative
17 Right Colon Cancer T3 N1 M0 III positive negative
22 Synchronous liver metastasis from Colon 
Cancer
T3 N2 M1 IV negative positive
23 Metachronous liver metastasis from 
Rectal Cancer
Tx Nx M1 IV negative positive
25 Right Colon Cancer T4 N2 M0 III positive negative
28 Synchronous liver and bone metastasis 
from Colon Cancer
Tx Nx M1 IV positive negative
31 Rectal cancer T1 N0 M0 I negative positive
32 Metachronous liver metastasis from 
Rectal Cancer
Tx Nx M1 IV positive negative
37 Metachronous liver metastasis from 
Rectal Cancer
Tx Nx M1 IV negative positive
Table 3: Comparison of tumor cell detection with UICC stage of CRC patients after enrichment with mAb BerEP4 and KS14 
coated beads.
UICC-Stage NO. OF PATIENTS POSITIVE CK20 SAMPLES
BerEP4 KS1/4
I702
I I700
III 7 3 0
IV 18 3 3Antolovic et al. BMC Biotechnology 2010, 10:35
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the detection rate of CTC. Additional investigations to
assess the variations of EpCAM molecule expression
among different patients will be of critical importance to
identify a panel of suitable mAbs which could be used for
efficient and reliable CTC isolation.
Our results also demonstrate that Ficoll-gradient isola-
tion is a decisive step prior to the immunomagnetic
enrichment of CTC from peripheral blood.
Conclusions
Our study for the first time shows that isolation and
detection of CTC with immunomagnetic enrichment
methods is critically dependent on the used EpCAM
clone. Further analysis regarding the clinical importance
of heterogenous expression of the EpCAM molecule in
CTC of CRC patients is urgently needed.
Methods
Blood samples from healthy donors and patients
For blood spiking experiments and for testing the speci-
ficity of the various extraction and enrichment protocols
peripheral blood samples were drawn from the antecu-
bital vein of 5 healthy donors and collected in EDTA-
coated tubes (S-Monovette®, Sarstedt, Germany). To
avoid epithelial cell contamination from skin puncture,
the first 5 ml of peripheral blood were discarded. After
collection, blood samples were immediately processed for
further experiments.
Five ml blood samples were obtained after induction of
general anesthesia (and before start of the operation)
through a central venous line from 38 CRC patients
(UICC stage I-IV) undergoing surgical therapy at the
Department of Surgery, University of Heidelberg, Ger-
many. Patients with histopathologically confirmed CRC
were staged according to the classification of the UICC
(6th edition) [28]. The study protocol was approved by the
ethics committee of the University of Heidelberg.
Informed consent for blood sampling was obtained from
each patient.
Cell spiking experiments
For cell spiking experiments and the examination of dif-
ferent cell extraction methods, EpCAM and CK20 posi-
tive cells from the human colon cancer cell line HT29
were serially diluted in 5 ml blood samples taken from
five different healthy donors. Dilutions performed were:
106, 105, 104, 103, 102, 10 and 0 HT29 cells per 5 ml whole
blood.
HT29 cells
The human colon cancer cell line HT29 expressing
EpCAM and Cytokeratin 20 (CK20) was purchased from
American Type Cell Culture (Austria Branch). Cells were
cultured in RPMI-1640 Medium with L-glutamine and
HEPES (PAA Laboratories GmbH, Austria) supple-
mented with 100 U/ml penicillin, 100 μg/ml streptomycin
(PAA Laboratories GmbH, Austria), and 10% fetal bovine
serum (Biochrom AG, Germany) in plastic flasks at 37°C
in a 5%CO2  atmosphere. Collection of cells was per-
formed with help of Trypsin-EDTA (PAA Laboratories
GmbH, Austria) and centrifugation at room temperature
for 3 minutes at 300 g. Cells were then counted with a
hemacytometer and viability was confirmed by Trypan
blue stain.
Mononuclear cell collection
The mononuclear cell (MNC) population was extracted
according to the following protocol: 5 ml peripheral
blood samples were carefully layered over a 15 ml Ficoll
gradient (FicoLite-H®, Linaris, Germany density 1.077)
and covered with 10 ml phosphate buffered saline solu-
tion (PBS; PAA Laboratories GmbH, Austria). The sam-
ples were spun in a centrifuge at 4°C for 30 minutes at 300
g without brake. Concentrated MNCs were harvested
from the interface with the help of a disposable pipette.
The isolated cells were washed once in PBS, spun in a
centrifuge for 10 minutes at 300 g and resuspended in 1
ml PBS. The MNCs were counted with a hemacytometer
and then resuspended at 107 cells/ml in PBS.
Immunomagnetic enrichment and cell extraction protocols
The unspiked and spiked (with HT29 cells) blood sam-
ples (5 ml blood for each experiment) of healthy volun-
teers were processed using two different cell extraction
protocols followed by immunomagnetic enrichment
using the device of Dynal MPC-L (Dynal, Norway):
1. Whole blood samples underwent directly an immu-
nomagnetic enrichment (107  beads per ml blood)
using either Dynabeads Epithelial Enrich (Dynal,
Oslo, Norway) coated with mAb BerEP4 or alterna-
tively, Pan Mouse IgG beads (Dynal, Norway) coated
(1 μg antibody/107 beads) with the mAb KS1/4 (BD
PharMingen, Heidelberg, Germany). The samples
were then placed in a roller at 4°C for rosetting to
occur and after 30 minutes the tubes were placed in a
magnetic device for 3 minutes; the blood supernatant
was carefully removed and, while the tubes were still
on the magnet, rosettes were washed three times with
cold PBS.
2. The isolated MNC fraction of the blood sample was
counted and resuspended with 107  beads, mAb
BerEP4 Dynabeads Epithelial Enrich or alternatively,
with Pan Mouse IgG beads coated with the mAb KS1/
4, per 107 MNCs in 1 ml PBS. Further immunomag-
netic processing was done in the same way as
described above.
Finally, the rosetted cells were pelleted by centrifuga-
tion at 300 g for 10 minutes and resuspended in 100 μlAntolovic et al. BMC Biotechnology 2010, 10:35
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PBS. Immediately, the samples were processed for RNA
isolation.
In all blood samples from CRC patients isolation of the
MNC fraction (prior to immunomagnetic enrichment
using the two different EpCAM antibodies) was per-
formed prior to further immunomagnetic enrichment.
Immunomagnetic enrichment using the two different
EpCAM antibodies was performed as described above.
RNA extraction and nested RT-PCR
CK20 transcripts were detected after immunomagnetic
enrichment of tumor cells either derived from blood sam-
ples spiked with HT29 cells or from blood samples drawn
from CRC patients.
For the detection of tumor cells a CK 20 nested RT-
PCR was performed as previously shown [12,13]. In brief,
total RNA was extracted from the cells immobilized by
the magnetic beads added to whole blood or MNC frac-
tions. RNeasy Mini Kit (Qiagen, Hilden, Germany) was
used to isolate total RNA according to the manufacturer's
instructions. Each sample was eluted in 30 μl RNase-free
water. For reverse transcription of the RNA the primer
CK20 558.rev and the SuperScript II Kit (Invitrogen,
Karlsruhe, Germany) was used following manufacturer's
i n s t r u c t i o n s.  2  μ l  a l i q u o t s  o f  c D N A  w e r e  u s e d  f o r  t h e
CK20 nested-PCR reaction using the Master Mix Kit
from Promega (Wisconsin, USA) according to manufac-
turer's protocol.
For the first PCR cDNA was subjected to amplification
of CK20 with primers 1.for (ATGGATTTCAGTCG-
CAGA) and 558.rev (ATGTAGGGTTAGGTCATCAA
AG) in 35 amplification rounds performed at 93°C for 51
seconds, 60°C for 63 seconds, and 72°C for 42 seconds,
with a final extension step at 72°C for 10 minutes. The
nested PCR was performed with 8 μl PCR product of the
first PCR with primer 139.for (TCCAACTCCAGACA-
CACGGTGAACTATG) and 429.rev (CAGGACACA
CCGAGCATTTT GCAG) under amplification condi-
tions as following: 93°C for 51 seconds and 72°C for 81
seconds in 35 amplification rounds. PCR products were
analyzed by electrophoresis on 2% agarose gels. RNA
quality and performance of reverse transcription of the
analyzed samples was confirmed by RT-PCR amplifica-
tion of GAPDH transcripts.
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